Callio Therapeutics | Multi-payload antibody-drug conjugates Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187 0 million Series A financing round
Callio gets in on the dual payload action | ApexOnco - Clinical Trials . . . Singapore-headquartered Hummingbird will continue developing its monoclonal antibodies, HMBD-001 and HMBD-002, and also retains rights to its ADC technology for non-oncology uses, a spokesperson for Seattle-based Callio told ApexOnco
Callio Therapeutics Doses First Patient in Phase I Clinical . . . - BioSpace Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from Callio Therapeutics dual-payload ADC pipeline to enter the clinic; Phase I trial is ongoing in Australia and the U S , with planned expansion to China; IND clearance received from the U S Food and
Callio Therapeutics Begins Phase I Trial of ADC in HER2-Expressing . . . NEW YORK – Callio Therapeutics on Tuesday started treating patients in a Phase I trial of its dual payload antibody-drug conjugate (ADC) CLIO-8221 in patients with advanced HER2-expressing solid tumors The Phase I II trial will include approximately 300 patients with HER2-positive metastatic or unresectable disease